<DOC>
	<DOCNO>NCT01483950</DOCNO>
	<brief_summary>This study non-interventional study patient treat HMGCoA reductase inhibitor ( rosuvastatin , simvastatin , atorvastatin fluvastatin ) available Bosnia Herzegovina least 6 month . Data collection patient take place single visit . The investigator complete Case Report Form ( CRF ) patient 's demographic , presence factor high cardiovascular risk , current treatment , cholesterol value well treatment decision .</brief_summary>
	<brief_title>Evaluation Patients Treated With HMG-CoA Reductase Inhibitors Reach Cholesterol Target Values</brief_title>
	<detailed_description>Non-interventional study ass reach cholesterol target value patient treat HMG-CoA reductase inhibitor Bosnia Herzegovina</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Patients , treat one HMGCoA reductase inhibitor least 6 month without change dose last 4 week least All patient must sign informed consent form Patients sign Informed Consent Form Patients contraindication treatment HMGCoA reductase inhibitor per SmPC approve Bosnia Herzegovina</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Statins</keyword>
	<keyword>Total Cholesterol</keyword>
	<keyword>Low density lipoprotein ( LDL ) cholesterol</keyword>
	<keyword>High density lipoprotein ( HDL ) cholesterol</keyword>
</DOC>